EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2013 Results
11 February 2014 - 12:41AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today details relating to its fourth quarter
and full year 2013 results announcement, which will take place on
Thursday, April 3, 2014, before the opening of the market.
EDAP will hold a conference call on Thursday, April 3, 2014 at
8:30 a.m. EDT to discuss the results. The dial-in numbers are
1-877-300-8521 for domestic callers and 1-412-317-6026 for
international callers. The conference ID number for both is
10040166. A live webcast of the conference call will be
available online from the investor relations page of the Company's
corporate website at www.edap-tms.com.
After the live event, the webcast will remain available on
EDAP's website, www.edap-tms.com, through May 1, 2014. In
addition, a telephonic replay of the call will be available until
April 10, 2014. The replay dial-in numbers are 1-877-870-5176
for domestic callers and 1-858-384-5517 for international
callers. Please use event passcode 10040166.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment, Ablatherm-HIFU is approved and
commercialized in Europe as a treatment for prostate cancer and is
currently under regulatory review in the U.S. following submission
of the Pre-Market Approval Application in February 2013 after the
completion of a multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA.
In February 2013, the Company introduced a new innovative HIFU
device, the Focal One® dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the Company,
please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. Such statements are based on management's current
expectations and are subject to a number of uncertainties,
including the uncertainties of the FDA PMA review process, our
ability to expand our U.S. operations and execute our growth
strategy and the market potential for our medical technologies, as
well as risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors
that may cause such a difference include, but are not limited to,
those described in the Company's filings with the Securities and
Exchange Commission and in particular, in the sections "Cautionary
Statement on Forward-Looking Information" and "Risk Factors" in the
Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is
in clinical trials, but not FDA-approved or marketed in the United
States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
The Ruth Group
David Burke/Stephanie Carrington
646-536-70009/7017
dburke@theruthgroup.com
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024